News Releases

Click here to access press releases from Astellas Pharma Inc. located in Tokyo, Japan.

Month Year

Oct 19, 2020

New Roxadustat Data in Anemia of Chronic Kidney Disease to be Released at ASN Kidney Week 2020 Reimagined

42 abstracts featuring additional insights into roxadustat and anemia of chronic kidney disease to be presented
Oct 12, 2020

Astellas and Seagen Announce Positive Topline Results from Second Cohort of Patients in Phase 2 Pivotal Trial of PADCEV® (enfortumab vedotin-ejfv) in Advanced Urothelial Cancer

- Durable Responses Observed in Patients Who Had Previously Received Immunotherapy but Were Ineligible for Cisplatin in Locally Advanced or Metastatic Setting -
Oct 8, 2020

Astellas and LabCentral Announce Golden Ticket Winners - Helping Emerging Biotechs Accelerate Growth of Innovative Science

- AXONIS Therapeutics, Inc. and Tenza win a year of access to life-science incubator in Cambridge, MA and access to Astellas expertise to further their research -
Oct 1, 2020

Astellas Celebrates First-Ever Virtual Day of Service to Help Non-Profit Organizations Respond to Local Community Needs

- 11th Annual Changing Tomorrow Day Enables Employees to Support Frontline Workers in Hospitals, Homeless and Hospitalized Veterans and Others in Need -
- Photos 1
Sep 29, 2020

Astellas and MBC BioLabs Announce Golden Ticket Competition to Help Biotech Start-ups Accelerate Early Drug Discovery and Research Efforts

Sponsorship provides a year of access to MBC BioLabs' life-science incubators and in-house Astellas expertise for scientific innovators
Sep 28, 2020

Astellas' Real-World Evidence Studies Provide Further Insight into Negative Impacts of Vasomotor Symptoms (VMS) Associated with Menopause

New findings to be presented at The North American Menopause Society (NAMS) 2020 Virtual Annual Meeting
Sep 23, 2020

Astellas Establishes Global Patient Centricity Leadership Structure to Incorporate Patient Perspectives Across Research and Development Continuum
- Photos 1
Sep 18, 2020

Astellas and Seattle Genetics Announce PADCEV® (enfortumab vedotin-ejfv) Significantly Improved Overall Survival in Phase 3 Trial in Previously Treated Locally Advanced or Metastatic Urothelial Cancer

- Trial Stopped Early Due to Positive Results at Planned Interim Analysis -
Sep 15, 2020

Astellas Ranks Among Top Companies for Working Parents
Sep 1, 2020

The Astellas Global Health Foundation Provides $2 Million In COVID-19 Relief To Six Organizations Serving More Than 725,000 Lives In Vulnerable Communities In Seven Countries

Recent grants and redirected funding help to respond to the COVID-19 pandemic by improving healthcare infrastructure, training and education in low-income countries

Show per page

Statements

Careers

Stay Connected

Get only the email alerts you want.

Media Contacts

corporate.communications@astellas.com

800-888-7704
(press menu option 5, then option 2)
This line is monitored between 8:00am-4:30-pm Central Time M-F

For inquiries during non-business hours, please contact us

Download Fact Sheet

Sustainability

Investors

Explore U.S. Products